Asleh K, et al. - Researchers assessed the ability of basal biomarkers nestin and inositol-polyphosphate-4-phosphate (INPP4B) to identify patients with metastatic breast cancer that would benefit from gemcitabine. To evaluate the prognostic and predictive abilities of biomarkers relative to treatment, they used the interaction tests, Kaplan-Meier curves, and forest plots. They identified 239 evaluable cases and, among these, 36 (15%) were categorized as basal-like by PAM50. Forty-one (17%) of the total cases were found to be “Nestin+ or INPP4B−”, which was significantly linked to PAM50 basal-like subtype. Significantly better overall survival on gemcitabine-docetaxel vs docetaxel monotherapy was seen in patients designated as immunohistochemistry basal “nestin+ or INPP4B-” within an estimated median follow-up of 13 years, while no differences were seen for other patients.